Sulfasalazine is a medicine that combines two active components - sulfapyridine (a sulfonamide antibiotic) and 5-aminosalicylic acid (5-ASA, also called mesalazine) linked together by an azo bond. It was first synthesised in the 1930s and remains one of the oldest disease-modifying antirheumatic drugs (DMARDs). It is used to treat rheumatoid arthritis, ulcerative colitis, Crohn's disease and juvenile idiopathic arthritis.

Drug Class: DMARD and Anti-Inflammatory Dual Role

Sulfasalazine occupies a dual pharmacological role. In rheumatology, it is classified as a conventional synthetic disease-modifying antirheumatic drug (csDMARD) - a drug that modifies the underlying disease process in rheumatoid arthritis rather than simply relieving symptoms. In gastroenterology, it is classified as an aminosalicylate, a local anti-inflammatory agent for the bowel. This dual role reflects the fact that its two components exert their effects in different ways: sulfapyridine is largely responsible for the systemic anti-inflammatory and immunomodulatory effects relevant to arthritis whereas 5-ASA acts locally in the bowel to reduce intestinal inflammation.

Medical Uses

Doctors prescribe sulfasalazine for:

• Rheumatoid arthritis (RA): Sulfasalazine is a first-line DMARD for RA, particularly for early or moderate disease; it reduces joint swelling, pain and the rate of joint damage

• Ulcerative colitis (UC): Used to induce and maintain remission in mild-to-moderate UC; the 5-ASA component acts locally on the inflamed colonic mucosa

• Crohn's disease: Sulfasalazine is modestly effective for Crohn's disease affecting the colon; less effective for small bowel Crohn's than for colonic disease

• Juvenile idiopathic arthritis (JIA): Used in children above 6 years under specialist supervision, particularly for oligoarticular and polyarticular subtypes

• Psoriatic arthritis and ankylosing spondylitis: Modestly effective as a peripheral joint DMARD but does not prevent spinal damage.

Gastro-Resistant (Enteric-Coated) Tablets - Why They Matter

Sulfasalazine is available as plain (uncoated) tablets and as gastro-resistant (enteric-coated) tablets (EC). Plain tablets are absorbed from the upper gastrointestinal tract before reaching the colon. On the other hand gastro-resistant tablets pass through the stomach intact and release the drug in the small intestine and colon. For bowel conditions (ulcerative colitis, Crohn's disease affecting the colon) gastro-resistant tablets deliver more drug to the site of inflammation and are better tolerated. 

For rheumatoid arthritis either form can be used but gastro-resistant tablets significantly reduce nausea and upper gastrointestinal side effects that are the most common reason patients stop the drug early. In India, gastro-resistant 1000 mg tablets are widely used for rheumatoid arthritis.

How Sulfasalazine Works at the Molecular Level

After oral ingestion, sulfasalazine reaches the colon largely intact, where bacterial azo-reductases cleave the azo bond and release sulfapyridine and 5-ASA. In rheumatoid arthritis, sulfapyridine is absorbed systemically and exerts multiple immunomodulatory effects: it inhibits the production of pro-inflammatory cytokines including IL-1, IL-6, and TNF-alpha; inhibits neutrophil and lymphocyte function; and reduces the production of rheumatoid factor. In ulcerative colitis, 5-ASA acts locally to inhibit prostaglandin synthesis and neutrophil chemotaxis, reducing mucosal inflammation. The therapeutic effects in RA typically begin to appear after 6 to 12 weeks.

Side Effects and How to Manage Them

Common complications are:

• Nausea and vomiting: The most common side effects; minimised by using gastro-resistant tablets, starting at a low dose (500 mg once daily) and increasing gradually over 4 to 8 weeks and taking the tablets with food

• Anorexia and abdominal discomfort: Common at the start of treatment; usually improves within a few weeks

• Headache and dizziness: Typically transient; most common in the first few weeks of treatment

• Orange-yellow discolouration of urine, skin and soft contact lenses: Caused by the azo dye metabolites of sulfasalazine; harmless but alarming to patients who are not warned in advance; soft contact lenses can be permanently stained

• Reversible reduction in sperm count (oligospermia): Occurs in many men on sulfasalazine; the oligospermia is reversible within 2 to 3 months of stopping the drug; male patients planning fertility should discuss switching to an alternative DMARD with their rheumatologist.

Serious Risks: Blood Count Changes and Liver Effects

In some cases sulfasalazine might cause serious complications. They are:

• Haematological toxicity: Sulfasalazine can cause leucopenia (low white blood cell count), neutropenia, thrombocytopenia (low platelet count) and rarely agranulocytosis (near-complete loss of neutrophils); haematological toxicity is most common in the first 3 months; regular blood count monitoring is mandatory

• Haemolytic anaemia: The sulfapyridine component can cause red blood cell destruction particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Therefore G6PD status should be checked before starting sulfasalazine in at-risk patients

• Hepatotoxicity: Elevated liver enzymes (ALT, AST) can occur; severe liver injury is rare but documented; liver function must be monitored during the first 6 months of treatment

• Pulmonary toxicity: Rare pneumonitis (lung inflammation) characterised by breathlessness and cough; the drug should be stopped immediately if suspected

• Stevens-Johnson syndrome and toxic epidermal necrolysis: Rare but life-threatening skin reactions; associated with sulfonamide sensitivity; requires immediate withdrawal and emergency management.

Who Should Not Take Sulfasalazine? 

A certain group of people should avoid taking sulfasalazine. They are:

• Patients with sulfonamide (sulfa drug) allergy: Sulfasalazine contains sulfapyridine, a sulfonamide so patients with a documented hypersensitivity reaction to any sulfa drug are at risk of cross-reacting to sulfasalazine; the reaction can include rash, fever and severe hypersensitivity reactions

• Patients with porphyria: Sulfasalazine can precipitate acute attacks

• Patients with severe renal or hepatic impairment: Reduced elimination increases toxicity risk

• Infants under 2 years: Sulfonamides displace bilirubin from protein binding, increasing the risk of kernicterus (bilirubin brain damage)

• Patients with salicylate hypersensitivity: The 5-ASA component is chemically related to aspirin; patients with aspirin hypersensitivity should use sulfasalazine cautiously or avoid it.

Drug Interactions Worth Knowing

Key interactions are:

• Azathioprine

• Cyclosporine

• Digoxin

• Folate antagonism 

• Insulin

• Live vaccines

• Methotrexate 

• Phenytoin

• Rifampicin

• Sulfonylureas

• Warfarin.

FAQs

1. What is sulfasalazine used to treat?

   Sulfasalazine is commonly used for inflammatory conditions (rheumatoid arthritis, ulcerative colitis and others). It works by reducing inflammation 

   in the body thus giving you relief from pain & swelling over time.

2. How long does sulfasalazine take to work for arthritis?

   Most people start noticing real improvement after about six to twelve weeks of regular use so it's important to keep taking it consistently even if early results feel slow to show.

3. Can sulfasalazine change the colour of urine or skin?

   Yes and this is completely normal. Sulfasalazine can turn urine a yellow-orange shade and may even tint the skin slightly. It looks alarming at first but it's a harmless side effect of the medication.

4. Is sulfasalazine a steroid or painkiller?

   Sulfasalazine belongs to a group of drugs (DMARDs) that target inflammation at its source rather than just masking pain. That is why it is different from steroids or standard painkillers.

5. What blood tests are needed while taking sulfasalazine?

   Regular blood tests are important for monitoring liver function, kidney health and blood cell counts. These tests catch any side effects early so doctors usually schedule them periodically throughout treatment.

6. Can someone with a sulfa allergy take sulfasalazine?

   Anyone with a known sulfa allergy should generally avoid sulfasalazine as it contains a sulfa component and could trigger a serious allergic reaction. 

7. Is sulfasalazine safe during pregnancy or breastfeeding?

   Sulfasalazine is one of the relatively safer DMARDs during pregnancy and is used for rheumatoid arthritis and inflammatory bowel disease in pregnant women. It must always be combined with folic acid supplementation (5 mg daily) because it impairs folate absorption, which is critical for foetal neural tube development. Sulfasalazine passes into breast milk in small amounts; breastfeeding is generally considered acceptable during sulfasalazine use, though the infant should be monitored for jaundice.

8. What is the difference between sulfasalazine plain tablets and gastro-resistant tablets?

   Gastro-resistant tablets have a special coating that protects the stomach lining and reduces irritation whereas plain tablets dissolve earlier in digestion. Doctors often choose gastro-resistant tablets for patients with bowel conditions and sensitive stomachs.

9. Can sulfasalazine be used for children with juvenile arthritis?

   Yes it's sometimes prescribed for children with juvenile arthritis though dosing is carefully adjusted based on the child's weight and needs. A paediatric specialist should always oversee treatment closely.

10. What happens if sulfasalazine is stopped suddenly?

    If you are stopping sulfasalazine suddenly your symptoms can flare up as it requires consistent use to keep inflammation under control. Any changes to dosage or stopping treatment should always be discussed with a doctor first.

References

1. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99. https://doi.org/10.1136/annrheumdis-2019-216655

2. Peppercorn MA. Sulfasalazine: pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med. 1984;101(3):377–86. https://doi.org/10.7326/0003-4819-101-3-377

3. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997;350(9074):309–18. https://doi.org/10.1016/S0140-6736(97)01300-7

4. Indian Rheumatology Association. Evidence-based management guidelines for rheumatoid arthritis in India. Int J Rheum Dis. 2019;22(Suppl 1):1–26. https://doi.org/10.1111/1756-185X.13502

5. Gotlib V, Khaled Y, Gotlib J. Sulfasalazine in pregnancy — an updated review. Ther Adv Drug Saf. 2013;4(4):168–74. https://doi.org/10.1177/2042098613483841